Why is Navi Medical Technologies raising A$6.8 million?

Navi Medical Technologies is raising A$6.8 million to fund manufacturing expansion, build a US commercial team and support the launch of its Neonav paediatric vascular access technology into leading children’s hospitals after securing FDA 510(k) clearance.

What are the key details of Navi Medical Technologies’ capital raise?

The A$6.8 million round for Navi Medical Technologies was led by healthcare venture capital firm KP Rx with A$4 million, alongside Innovation Victoria and Pacific Channel, and is focused on commercialising Neonav in the United States during 2026.

How does Neonav work according to Navi Medical Technologies?

Navi Medical Technologies says Neonav uses real‑time intravascular ECG to guide catheter tip placement and combines this with ongoing migration surveillance, enabling clinicians to monitor and reassess catheter position throughout use and potentially reduce repeat X‑ray imaging.

What clinical need is Navi Medical Technologies targeting with Neonav?

Navi Medical Technologies is targeting the challenge of accurate central venous access in neonatal and paediatric intensive care, noting that misplacement or migration of catheters can cause serious complications and that current ECG‑guided systems are mainly designed for adult patients.

What does FDA clearance mean for Navi Medical Technologies and Neonav?

Navi Medical Technologies says the initial FDA 510(k) clearance and subsequent expanded indication allow Neonav to be used for a broad range of paediatric and neonatal vascular access procedures in the US, opening the world’s largest healthcare market for commercial sales.

Image for illustrative purposes only. Not a real photo.

Navi raises A$6.8m to launch paediatric catheter tech in US

Written by Brie CarterPublished Jul 29, 2026, 3:55 AM

Navi Medical Technologies has raised A$6.8 million to fund US commercialisation of its Neonav paediatric vascular access system after securing FDA 510(k) clearance.
The round was led by healthcare VC firm KP Rx with a A$4 million investment, alongside Innovation Victoria and Pacific Channel.
Navi said the capital will expand manufacturing, build its US commercial team and support Neonav’s rollout into leading children’s hospitals, with initial sales expected this year.

Navi Medical Technologies has closed a A$6.8 million capital raise to support commercialisation of its Neonav ECG‑guided paediatric vascular access technology in the United States following FDA 510(k) clearance and early clinical evaluations.

The company said the funding round was led by KP Rx with A$4 million, joined by existing investor Innovation Victoria and New Zealand‑ and Melbourne‑based Pacific Channel.

It follows Neonav’s expanded US indication covering a broader range of neonatal and paediatric vascular access procedures.

“Navi has developed a genuinely differentiated technology addressing a significant unmet clinical need,” said KP Rx Partner Hashan De Silva, who described Neonav as positioned to become an important tool in neonatal and paediatric vascular access.

Navi stated that the funds will be used to scale Neonav manufacturing, build a US commercial team and support product launch into leading US children’s hospitals, with commercial sales expected to begin later this year as clinical evaluation sites convert to early customers.

The company said Neonav combines real‑time ECG‑guided catheter tip placement with ongoing migration surveillance, allowing clinicians to reassess catheter position throughout use and potentially reduce repeat imaging and complications from misplacement or movement.